Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Friday, August 5, 2022 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, August 4, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2022 to August 6, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the first quarter ended June 30, 2022. The above is for your information. Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2022.
Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, August 4, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2022 to August 6, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the first quarter ended June 30, 2022. The above is for your information. Glenmark Life Sciences Ltd - 543322 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0211 Name of the Signatory :- Rudalf CorrieaDesignation :- Company Secretary and Compliance Officer Glenmark Life Sciences Ltd - 543322 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In Compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended March 31, 2022, in the required format. Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 31st March, 2022 in respect of utilization of proceeds of the IPO of the Company. Glenmark Life Sciences Ltd - 543322 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Annual Secretarial Compliance Report for the year ended 31st March, 2022. Glenmark Life Sciences Ltd - 543322 - Audio Recordings Of Q4 & FY22 Earnings Call
Pursuant to Regulation 30 and 46 read with clause 15 of Para A of Part A of Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that we have uploaded audio recording of the Q4 & FY22 Earnings Call held on April 21, 2022, on our investor website : https://www.glenmarklifesciences.com/financial-results.php under Financial Results. We request you to take note and host the same on your website. Q4FY22 Quarterly Result Announced for Glenmark Life Sciences Ltd.
Glenmark Life Sciences reports revenue growth of 10% YoY for Q4 FY22, 12.6% for the full year FY22 Glenmark Life Sciences Pharmaceuticals declares Q4FY22 result: Glenmark Life Sciences reports revenue growth of 10% YoY for Q4 FY22; 12.6% for the full year, FY22 GLS registered revenue from operations of Rs 5,140.6 Mn for Q4FY22, recording a YoY growth of 10% and, Rs 21,232.1 Mn for FY22, a growth of 12.6%. Revenues from the Generic API segment increased by 12.1% and the CDMO business registered a growth of 12.4% in FY22. During FY22, revenues from the regulated markets witnessed a healthy growth of 21.4% YoY, whereas revenues from the emerging markets declined by 6.3% YoY due to high base of COVID products sales last year. Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) was at Rs 1,473.1 Mn for Q4FY22 with margin at 28.7% and Rs 6,307.6 Mn for FY22 with margin at 29.7%. Profit After Tax (PAT) was at Rs 989 Mn in Q4FY22, registering a de-growth of 5.5% YoY and Rs 4,187.2 Mn in FY22, a growth of 19.1% The Board has recommend a final Dividend of Rs 10.5 per equity share of face value of Rs 2/-, for the year ended 31st March, 2022. The total Dividend for the financial year ended 31st March, 2022 amounts to Rs 21 per share of face value of Rs 2/- each. Commenting on the company’s performance, Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited said, “At Glenmark Life Sciences, we had a good quarter and sustained a healthy and profitable growth for the full year, FY22, despite a challenging business environment. For FY22, we continued to witness a healthy EBITDA margin, a strong momentum in the CDMO business and growth in regulated markets. The PAT margins for FY22 also improved on the back of debt repayment. Clearly, our business performance is a reflection of the depth of our portfolio and our ability to drive business across geographies and customer segments.” Dr. Rawjee further added, “We are set to enter FY23 powered through continued execution on our key priorities in R&D; and Operations, via product portfolio expansion and new launches. Further we remain on track on our future expansion plans and are confident of a solid growth trajectory.” According to Bhavesh Pujara, CFO, Glenmark Life Sciences Limited, “Our business delivered a top-line growth of 10% during the quarter and 12.6% for FY22 over a high base of COVID product sales last year. We kept our focus on cost controls and productivity to overcome headwinds from high input costs and energy prices. Our EBITDA margin was 28.7% for the quarter and 29.7% for the year FY22. We have also significantly ramped up capital expenditure to support our growth plans. Overall, we have closed the year on a healthy note with robust demand momentum, sustaining robust EBITDA margins and strong cash flows” Result PDF Glenmark Life Sciences Ltd - 543322 - Board recommends Final Dividend
Glenmark Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 20, 2022, inter alia, has recommended final Dividend of Rs. 10.50 per share (face value of Rs. 2/- each) on the Equity Share Capital of the Company for the financial year 2021 - 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting.